Latest OLMA reports update at 2024-05-08: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Olema Pharmaceuticals OLMA

$ 9.84 -9.31%

Olema Pharmaceuticals Financial Statements 2011-2024 | OLMA

Annual Financial Statements Olema Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	588 M	150 M	254 M	856 M	-	-	-	-	-	-	-	-	-
Shares	45.2 M	40 M	39.5 M	20.2 M	-	-	-	-	-	-	-	-	-
Historical Prices	13	3.74	6.43	42.5	-	-	-	-	-	-	-	-	-
Net Income	-96.7 M	-105 M	-71.1 M	-22.1 M	-4.32 M	-2.2 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-105 M	-107 M	-71.5 M	-21.5 M	-4.32 M	-	-	-	-	-	-	-	-
Interest Expense	-19 K	-27 K	-47 K	653 K	-	-	-	-	-	-	-	-	-
EBITDA	-105 M	-107 M	-71.3 M	-21.5 M	-4.31 M	-2.07 M	-	-	-	-	-	-	-
Operating Expenses	105 M	107 M	71.5 M	21.5 M	4.32 M	2.08 M	-	-	-	-	-	-	-
General and Administrative Expenses	18.8 M	24.7 M	20.4 M	7.82 M	403 K	386 K	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Olema Pharmaceuticals

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	55.6 M	55 M	45 M	40.7 M	40.4 M	40.3 M	40 M	39.9 M	39.8 M	39.8 M	39.6 M	39.4 M	39.3 M	39.3 M	2.62 M	2.59 M	2.59 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-31 M	-	-21.5 M	-20.1 M	-28.3 M	-	-22.7 M	-32.9 M	-23 M	-	-17.7 M	-16.4 M	-15.3 M	-	-7.84 M	-2.45 M	-1.69 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-34.3 M	-	-23.3 M	-21.6 M	-29.6 M	-	-23.2 M	-33.3 M	-23.3 M	-	-17.8 M	-16.5 M	-15.4 M	-	-7.87 M	-2.49 M	-1.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	17 K	-	-79 K	-44 K	11 K	-	-120 K	20 K	6 K	-	-56 K	-1 K	111 K	-	653 K	653 K	653 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-34.3 M	-	-	-	-29.5 M	-	-23 M	-33.1 M	-23.2 M	-	-17.7 M	-16.5 M	-15.4 M	-	-7.86 M	-2.48 M	-1.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	34.3 M	-	23.3 M	21.6 M	29.6 M	-	23.2 M	33.3 M	23.3 M	-	17.8 M	16.5 M	15.4 M	-	7.87 M	2.49 M	1.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	4.46 M	-	3.89 M	3.61 M	6.78 M	-	5.6 M	6.24 M	7.24 M	-	5.24 M	4.61 M	4.76 M	-	3.2 M	539 K	248 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency